FDA has concluded that Kemwell’s facility, systems, and practices comply with FDA’s requirements and no observations were reported on Form 483. CDMO, Kemwell, announced that its oral solid dosage ...
Milestone expands India’s role in global biologics manufacturing; collaboration with Cipla underscores commitment to quality and reliability BENGALURU, India, October 28, 2025--(BUSINESS ...
March 23, 2015 - Kemwell Biopharma Pvt. Ltd., a global bio/pharmaceutical contract development and manufacturing company, announced today that its oral solids manufacturing facility located in ...
Addition of the New Freeze Drying Capability Sets the Company on a Course to Expand Business From Both New and Existing Customers BANGALORE, March 13, 2014 /PRNewswire/ -- Kemwell Biopharma, a global ...
MALVERN, Pa., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure ...
The CDMO’s facilities will be used to accelerate the production for a treatment of nAMD. RevOpsis announced a strategic manufacturing partnership with Kemwell Biopharma, a CDMO. 1 This move will allow ...
Through two acquisitions, Recipharm will acquire Kemwell’s United States, Swedish, and Indian operations. Recipharm AB announced on April 18, 2016 that it has signed two separate agreements to acquire ...
Recipharm has signed two separate agreements to acquire Kemwell’s pharmaceutical contract development and manufacturing (CDMO) businesses. The first acquisition, comprising US and Swedish operations, ...
Kemwell Biopharma has announced that it has installed and qualified its commercial scale lyophilizer. With this expansion, Kemwell has added GMP lyophilization capability to its sterile injectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results